Related Articles by Review for PMID: 17206155

Year	Number of Results
2005	1
2007	3
2008	1
2009	1
2010	1
2011	1
2012	1
2014	3
2015	1
2016	1
2017	1
2020	1
2022	4
2023	2
2024	0

1

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.

Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM. Sergina NV, et al. Nature. 2007 Jan 25;445(7126):437-41. doi: 10.1038/nature05474. Epub 2007 Jan 7. Nature. 2007. PMID: 17206155 Free PMC article.

2

Targeting HER proteins in cancer therapy and the role of the non-target HER3.

Hsieh AC, Moasser MM. Hsieh AC, et al. Br J Cancer. 2007 Aug 20;97(4):453-7. doi: 10.1038/sj.bjc.6603910. Epub 2007 Jul 31. Br J Cancer. 2007. PMID: 17667926 Free PMC article. Review.

3

Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.

Subramaniam D, He AR, Hwang J, Deeken J, Pishvaian M, Hartley ML, Marshall JL. Subramaniam D, et al. Curr Cancer Drug Targets. 2015;14(9):775-93. doi: 10.2174/1568009614666141111104643. Curr Cancer Drug Targets. 2015. PMID: 25435079 Review.

4

A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy.

Claus J, Patel G, Ng T, Parker PJ. Claus J, et al. Biochem Soc Trans. 2014 Aug;42(4):831-6. doi: 10.1042/BST20140043. Biochem Soc Trans. 2014. PMID: 25109965 Review.

5

Human epidermal growth factor receptor 3 in head and neck squamous cell carcinomas.

Rysman B, Mouawad F, Gros A, Lansiaux A, Chevalier D, Meignan S. Rysman B, et al. Head Neck. 2016 Apr;38 Suppl 1:E2412-8. doi: 10.1002/hed.24367. Epub 2016 Feb 2. Head Neck. 2016. PMID: 26835877 Review.

6

An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).

Ferrer-Soler L, Vazquez-Martin A, Brunet J, Menendez JA, De Llorens R, Colomer R. Ferrer-Soler L, et al. Int J Mol Med. 2007 Jul;20(1):3-10. Int J Mol Med. 2007. PMID: 17549382 Review.

7

HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of Cancer.

Majumder A. Majumder A. Cells. 2023 Oct 25;12(21):2517. doi: 10.3390/cells12212517. Cells. 2023. PMID: 37947595 Free PMC article. Review.

8

Role of HER2/HER3 co-receptor in breast carcinogenesis.

Way TD, Lin JK. Way TD, et al. Future Oncol. 2005 Dec;1(6):841-9. doi: 10.2217/14796694.1.6.841. Future Oncol. 2005. PMID: 16556064 Review.

9

The HER family as therapeutic targets in colorectal cancer.

Ye P, Wang Y, Li R, Chen W, Wan L, Cai P. Ye P, et al. Crit Rev Oncol Hematol. 2022 Jun;174:103681. doi: 10.1016/j.critrevonc.2022.103681. Epub 2022 Apr 21. Crit Rev Oncol Hematol. 2022. PMID: 35462030 Review.

10

Molecular pathways: HER3 targeted therapy.

Gala K, Chandarlapaty S. Gala K, et al. Clin Cancer Res. 2014 Mar 15;20(6):1410-6. doi: 10.1158/1078-0432.CCR-13-1549. Epub 2014 Feb 11. Clin Cancer Res. 2014. PMID: 24520092 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

22 results

Results by year